Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Single Rising Inhaled Doses of Olodaterol in Healthy Volunteers
NCT02171780Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2005
- Primary completion
- Jul 2005
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing BI 1744 CL with Placebo (2 arms). Primary endpoints: Number of patients with abnormal findings in physical examination, Number of patients with clinically significant changes in vital signs and 10 more. Started Feb 2005; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02171780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171780.